// App-Quantinova.ai

TPS1111 : ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

Researchers

Presenter

  • Debu Tripathy

Principal Investigators

  • Sara M. Tolaney

  • Andrew David Seidman

  • Carey K. Anders

  • Nuhad K. Ibrahim

  • Hope S. Rugo

  • Chris Twelves

  • Veronique Dieras

  • Volkmar Mueller

  • Alison Hannah

  • Mary Ann Tagliaferri

  • Javier Cortes

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of North Carolina, Chapel Hill, NC

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Leeds and St. James's Institute of Oncology, Leeds, United Kingdom

  • Institut Curie, Paris Cedex, France

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Consultant, Sebastopol, CA

  • Nektar Therapeutics, San Francisco, CA

  • Ramon y Cajal University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Locations

  • Germany

  • Spain

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • UDP glucuronosyltransferase family 1 member A1

  • Circulating DNA

Drug/Treatment

  • etirinotecan pegol

  • Capecitabine

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • NCT02915744

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved